Investigation of the relationship of TNFRSF11A gene polymorphisms with breast cancer development and metastasis risk in patients with BRCA1 or BRCA2 pathogenic variants living in the Trakya region of Turkey

1Yararbas K, Atalay PB. Association of E-selectin S128R polymorphism with hereditary breast carcinoma susceptibility in Turkish patients without BRCA1/2 germline mutations. Balkan J Med Genet. 2018; 21(1): 27-32.YararbasKAtalayPBAssociation of E-selectin S128R polymorphism with hereditary breast carcinoma susceptibility in Turkish patients without BRCA1/2 germline mutationsBalkan J Med Genet2018211273210.2478/bjmg-2018-0004623130930425907Search in Google Scholar

2Armstrong N, Ryder S, Forbes C, Ross J, Quek RGw. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019;11:543-561.ArmstrongNRyderSForbesCRossJQuekRGwA systematic review of the international prevalence of BRCA mutation in breast cancerClin Epidemiol20191154356110.2147/CLEP.S206949662894731372057Search in Google Scholar

3Hughes DC. Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Fam Cancer. 2008; 7(3): 233-244.HughesDCUse of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriersFam Cancer20087323324410.1007/s10689-008-9181-018283561Search in Google Scholar

4Wittersheim M, Büttner R, Markiefka B. Genotype/ phenotype correlations in patients with hereditary breast cancer. Breast Care (Basel). 2015; 10(1): 2226.WittersheimMBüttnerRMarkiefkaBGenotype/ phenotype correlations in patients with hereditary breast cancerBreast Care (Basel)2015101222610.1159/000380900439581525960721Search in Google Scholar

5Hughes DJ, Ginolhac SM, Coupier I, Barjhoux L, Gaborieau V, Bressac-de-Paillerets B, et al. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and poly-glutamine repeat length in the AIB1 gene. Int J Cancer. 2005; 117(2): 230-233.HughesDJGinolhacSMCoupierIBarjhouxLGaborieauVBressac-de-PailleretsBet alBreast cancer risk in BRCA1 and BRCA2 mutation carriers and poly-glutamine repeat length in the AIB1 geneInt J Cancer2005117223023310.1002/ijc.2117615900600Search in Google Scholar

6Pristauz G, Petru E, Stacher E, Geigl JB, Schwarzbraun T, Tsybrovskyy O, et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations. Histopathology. 2010; 57(6): 877-884.PristauzGPetruEStacherEGeiglJBSchwarzbraunTTsybrovskyyOet alAndrogen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutationsHistopathology201057687788410.1111/j.1365-2559.2010.03724.x21166701Search in Google Scholar

7Ricks-Santi LJ, Sucheston LE, Yang Y, Freudenheim JL, Isaacs CJ, Schwartz MD, et al. Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk. BMC Cancer. 2011; 11: 278.Ricks-SantiLJSuchestonLEYangYFreudenheimJLIsaacsCJSchwartzMDet alAssociation of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer riskBMC Cancer20111127810.1186/1471-2407-11-278314693821708019Search in Google Scholar

8Bonifaci N, Palafox M, Pellegrini P, Osorio A, Benítez J, Peterlongo P, et al. Evidence for a link between TNFRSF11A and risk of breast cancer. Breast Cancer Res Treat. 2011; 129(3): 947-954.BonifaciNPalafoxMPellegriniPOsorioABenítezJPeterlongoPet alEvidence for a link between TNFRSF11A and risk of breast cancerBreast Cancer Res Treat2011129394795410.1007/s10549-011-1546-721541702Search in Google Scholar

9Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, et al. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem. 2005; 280(42): 35209-35216.KimKKimJHLeeJJinHMLeeSHFisherDEet alNuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesisJ Biol Chem200528042352093521610.1074/jbc.M50581520016109714Search in Google Scholar

10Geerts D, Chopra C, Connelly L. Osteoprotegerin: Relationship to breast cancer risk and prognosis. Front Oncol. 2020; 10: 462.GeertsDChopraCConnellyLOsteoprotegerin: Relationship to breast cancer risk and prognosisFront Oncol20201046210.3389/fonc.2020.00462715406732318347Search in Google Scholar

11Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007; 9(Suppl 1): S1.BoyceBFXingLBiology of RANK, RANKL, and osteoprotegerinArthritis Res Ther20079Suppl 1S110.1186/ar2165192451617634140Search in Google Scholar

12Willard D, Chen WJ, Barrett G, Blackburn K, Bynum J, Consler T, et al. Expression, purification, and characterization of the human receptor activator of NF-kappaB ligand (RANKL) extracellular domain. Protein Expr Purif. 2000; 20(1): 48-57.WillardDChenWJBarrettGBlackburnKBynumJConslerTet alExpression, purification, and characterization of the human receptor activator of NF-kappaB ligand (RANKL) extracellular domainProtein Expr Purif2000201485710.1006/prep.2000.127811035950Search in Google Scholar

13Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front Immunol. 2014; 5: 511.WalshMCChoiYBiology of the RANKL-RANK-OPG system in immunity, bone, and beyondFront Immunol20145511Search in Google Scholar

14Sigl V, Jones LP, Penninger JM. RANKL/RANK: From bone loss to the prevention of breast cancer. Open Biol. 2016; 6(11): 160230.SiglVJonesLPPenningerJMRANKL/RANK: From bone loss to the prevention of breast cancerOpen Biol201661116023010.1098/rsob.160230513344327881737Search in Google Scholar

15Kiesel L, Kohl A. Role of the RANK/RANKL pathway in breast cancer. Maturitas. 2016; 86: 10-16.KieselLKohlARole of the RANK/RANKL pathway in breast cancerMaturitas201686101610.1016/j.maturitas.2016.01.00126921922Search in Google Scholar

16Renema N, Navet B, Heymann MF, Lezot F, Heymann D. RANK-RANKL signalling in cancer. Biosci Rep. 2016; 36(4): e00366.RenemaNNavetBHeymannMFLezotFHeymannDRANK-RANKL signalling in cancerBiosci Rep2016364e0036610.1042/BSR20160150497460527279652Search in Google Scholar

17Sigl V, Owusu Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, et al. RANKL/ RANK control BRCA1 mutation-driven mammary tumors. Nature. 2016; 26(7): 761-774.SiglVOwusuBoaitey KJoshiPAKavirayaniAWirnsbergerGNovatchkovaMet alRANKL/ RANK control BRCA1 mutation-driven mammary tumorsNature201626776177410.1038/cr.2016.69512988327241552Search in Google Scholar

18Azim HA Jr, Peccatori FA, Brohée S, Branstetter D, Loi S, Viale G, et al. RANK ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res. 2015; 17: 24.AzimHAJrPeccatoriFABrohéeSBranstetterDLoiSVialeGet alRANK ligand (RANKL) expression in young breast cancer patients and during pregnancyBreast Cancer Res2015172410.1186/s13058-015-0538-7437417425849336Search in Google Scholar

19van Dam PA, Verhoeven Y, Trinh XB, Wouters A, Lardon F, Prenen H, et al. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2019; 133: 85-91.vanDam PAVerhoevenYTrinhXBWoutersALardonFPrenenHet alRANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatmentCrit Rev Oncol Hematol2019133859110.1016/j.critrevonc.2018.10.01130661662Search in Google Scholar

20Fardmanesh H, Shekari M, Movafagh A, Alizadeh Shargh S, Poursadegh Zonouzi AA, Shakerizadeh S. Up-regulation of the double-stranded RNA binding protein DGCR8 in invasive ductal breast carcinoma. Gene. 2016; 581(2): 146–151.FardmaneshHShekariMMovafaghAAlizadehShargh SPoursadeghZonouzi AAShakerizadehSUp-regulation of the double-stranded RNA binding protein DGCR8 in invasive ductal breast carcinomaGene2016581214615110.1016/j.gene.2016.01.03326804549Search in Google Scholar

21Toriola AT, Appleton CM, Zong X, Luo J, Weil-baecher K, Tamimi RM, et al. Circulating receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL), and mammographic density in pre-menopausal women. Cancer Prev Res (Phila). 2018; 11(12): 789-796.ToriolaATAppletonCMZongXLuoJWeil-baecherKTamimiRMet alCirculating receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL), and mammographic density in pre-menopausal womenCancer Prev Res (Phila)2018111278979610.1158/1940-6207.CAPR-18-0199678453330352839Search in Google Scholar

22Lu Y, Liu P, Recker RR, Deng HW, Dvornyk V. TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women. Menopause. 2010; 17(5): 1048-1054.LuYLiuPReckerRRDengHWDvornykVTNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white womenMenopause20101751048105410.1097/gme.0b013e3181d5d523293915620531232Search in Google Scholar

23Chung PY, Beyens G, Riches PL, Van Wesenbeeck L, de Freitas F, Jennes K, et al. Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget’s disease of bone. Bone Miner Res. 2010; 25(12): 2592-2605.ChungPYBeyensGRichesPLVanWesenbeeck LdeFreitas FJennesKet alGenetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget’s disease of boneBone Miner Res201025122592260510.1002/jbmr.16220564239Search in Google Scholar

24Lilyquist J, Ruddy KJ, Vachon CM, Couch FJ. Common genetic variation and breast cancer risk-past, present, and future. Cancer Epidemiol Biomarkers Prev. 2018; 27(4): 380-394.LilyquistJRuddyKJVachonCMCouchFJCommon genetic variation and breast cancer risk-past, present, and futureCancer Epidemiol Biomarkers Prev201827438039410.1158/1055-9965.EPI-17-1144588470729382703Search in Google Scholar

25Gayán J, Galan JJ, González-Pérez A, Sáez ME, Martínez-Larrad MT, Zabena C, et al. Genetic structure of the Spanish population. BMC Genomics. 2010; 11: 326.GayánJGalanJJGonzález-PérezASáezMEMartínez-LarradMTZabenaCet alGenetic structure of the Spanish populationBMC Genomics20101132610.1186/1471-2164-11-326288741820500880Search in Google Scholar

26Ney JT, Juhasz-Boess I, Gruenhage F, Graeber S, Bohle RM, Pfreundschuh M, et al. Genetic polymorphism of the OPG gene associated with breast cancer. BMC Cancer. 2013; 13: 40.NeyJTJuhasz-BoessIGruenhageFGraeberSBohleRMPfreundschuhMet alGenetic polymorphism of the OPG gene associated with breast cancerBMC Cancer2013134010.1186/1471-2407-13-40356362023369128Search in Google Scholar

27Rao S, Cronin SJF, Sigl V, Penninger JM. RANKL and RANK: From mammalian physiology to cancer treatment. Trends Cell Biol. 2018; 28(3): 213-223.RaoSCroninSJFSiglVPenningerJMRANKL and RANK: From mammalian physiology to cancer treatmentTrends Cell Biol201828321322310.1016/j.tcb.2017.11.00129241686Search in Google Scholar